Get the Stockscreener App
1.19
4.80%
-0.06
After Hours:
1.21
0.02
+1.68%
Geovax Labs Inc stock is traded at $1.19, with a volume of 248.31K.
It is down -4.80% in the last 24 hours and down -27.88% over the past month.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
See More
Previous Close:
$1.25
Open:
$1.22
24h Volume:
248.31K
Relative Volume:
0.05
Market Cap:
$6.20M
Revenue:
$852.30K
Net Income/Loss:
$-21.37M
P/E Ratio:
-0.0548
EPS:
-21.6981
Net Cash Flow:
$-19.06M
1W Performance:
-6.30%
1M Performance:
-27.88%
6M Performance:
-76.62%
1Y Performance:
-90.52%
1-Day Range:
$1.17
$1.23
1-Week Range:
$1.17
$1.325
52-Week Range:
$0.9631
$23.10
Geovax Labs Inc Stock (GOVX) Company Profile
Name
Geovax Labs Inc
Sector
Industry
Phone
678-384-7220
Address
1955 LAKE PARK DRIVE, SMYRNA
Compare GOVX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GOVX
Geovax Labs Inc
|
1.19 | 6.51M | 852.30K | -21.37M | -19.06M | -21.70 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Geovax Labs Inc Stock (GOVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Downgrade | D. Boral Capital | Buy → Hold |
| Apr-15-25 | Reiterated | Alliance Global Partners | Buy |
| Apr-15-25 | Reiterated | D. Boral Capital | Buy |
| Nov-11-24 | Initiated | Alliance Global Partners | Buy |
| Jul-16-24 | Initiated | ROTH MKM | Buy |
| Nov-19-20 | Initiated | Maxim Group | Buy |
View All
Geovax Labs Inc Stock (GOVX) Latest News
GeoVax Labs Company Profile & Introduction - Moomoo
GOVX Stock Became A Hot Biodefense Trade Amid Ebola, Hantavirus Concerns - Stocktwits
GOVX Should I Buy - Intellectia AI
Why Is GOVX Stock Falling Today? - Stocktwits
Price to earnings forward of GeoVax Labs, Inc. – NASDAQ:GOVX - TradingView
GeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine Readiness - Yahoo Finance
GOVX Q1 2026 Earnings: Narrower-Than-Expected Loss Bolsters Investor SentimentProduct Revenue Analysis - dars.gov.et
GeoVax Labs (GOVX) Stock Fair Value Moves Lower After Pipeline Shift - Yahoo Finance
GeoVax Labs, Inc. Actuals & Estimates (NASDAQ:GOVX) - TradingView
GEOVAX LABS INC (GOVX) Stock Chart - ChartMill
Price to book forward of GeoVax Labs, Inc. – NASDAQ:GOVX - TradingView
GOVX Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to EBIT forward of GeoVax Labs, Inc. – NASDAQ:GOVX - TradingView
Price to sales forward of GeoVax Labs, Inc. – NASDAQ:GOVX - TradingView
Form 4 GeoVax Labs Inc For: 22 June By Investing.com - Investing.com Australia
GeoVax (GOVX) director receives 6,000 stock options at $1.18 strike - Stock Titan
GeoVax (GOVX) director awarded 6,000 stock options at $1.18 exercise price - Stock Titan
GeoVax (GOVX) director awarded 6,000 stock options at $1.18 strike - Stock Titan
Director at GeoVax Labs (NASDAQ: GOVX) granted 6,000 options - Stock Titan
GeoVax Labs (GOVX) director gets grant of 6,000 stock options - Stock Titan
Director at GeoVax (GOVX) receives 6,000-share stock option grant - Stock Titan
GeoVax Labs (GOVX) VP receives grant of 17,600 stock options - Stock Titan
GeoVax Labs (GOVX) CFO awarded 17,600 stock options in new grant - Stock Titan
[Form 4] GeoVax Labs, Inc. Insider Trading Activity - Stock Titan
GeoVax (GOVX) CEO David Dodd granted 29,300 stock options at $1.18 strike - Stock Titan
GOVX Q1 2026 Earnings: EPS Surprises to the Upside by 41.89% as Stock Jumps 13.56%Guidance Downgrade Alert - dars.gov.et
GeoVax Labs Inc (GOVXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GeoVax Labs, Inc. Files Form 8-K with SEC: Company Details, Address, and NASDAQ Listing Information - Minichart
GeoVax Labs Inc (GOVX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GeoVax Labs Inc (GOVX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GeoVax Labs Inc (GOVX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GeoVax Labs Inc (GOVX) Valuation: PE, PB & Fair Value Analysis - TradingKey
GeoVax Labs Inc (GOVXW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GeoVax Labs Inc (GOVXW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GeoVax Labs Inc (GOVXW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GeoVax Labs (GOVX) shareholders approve major warrant share issuances and governance items - Stock Titan
GeoVax Labs Inc (GOVX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GeoVax Labs Inc (GOVX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GeoVax Labs Inc (GOVX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GeoVax Labs Inc (GOVX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GeoVax Labs Inc (GOVX) Institutional Confidence - TradingKey
GeoVax Highlights Strategic Implications of Gedeptin for Checkpoint-Resistant Cancers - citybuzz -
GeoVax Highlights Strategic Implications of Recent Gedeptin(R) Findings for Checkpoint-Resistant Cancers - Yahoo Finance
GeoVax Labs Inc (GOVXW) Valuation: PE, PB & Fair Value Analysis - TradingKey
GeoVax Labs Inc (GOVXW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GeoVax Labs Inc (GOVXW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
GeoVax Labs Inc (GOVXW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
GeoVax Labs Inc (GOVXW) Institutional Confidence - TradingKey
GOVX Q1 2026 Earnings: EPS Beat Driven by Lower-than-Expected Operating LossAnnual Report - newsline.com
GOVX Q1 2026 Earnings: EPS Surprise of 41.89% as Loss Narrows from EstimatesConsensus Forecast Report - newsline.com
GeoVax Labs (GOVX) could find a support soon, here's why you should buy the stock now - MSN
Geovax Labs Inc Stock (GOVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):